Back to all webinars
Next-generation BTK inhibitors for relapsed/refractory B-cell malignancies: What are the options and how do they compare?
Wojciech Jurczak, Federico Pea, Paolo Ghia and Alessandra Tedeschi review the role of BTK inhibition in the treatment of R/R B-cell malignancies, with a special focus on next-generation BTKis.
Speakers
What are the clinical implications of the different pharmacologic properties of BTK inhibitors?
Fast-forward to:
Molecular composition of BTK inhibitors and their mode of action
61af9e27f8742a0daf9e3b30
Molecular targets of BTK inhibitors
61afa4e82fc9050db56f8e1e
Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies, and safety and efficacy evaluation in CLL
61af9c9c3ebc500dae6c9a3e
Features and properties of zanubrutinib
61afa7aff8742a0daf9e3ba5
Drug–drug interactions with BTK inhibitors
61afa9d73ebc500dae6c9b96
Zanubrutinib vs. ibrutinib: Adverse events and potential mechanisms
61aface82fc9050db56f8f47
Pharmacologic properties of BTK inhibitors: Conclusions
61afb165f8742a0daf9e3cde
Next-generation BTK inhibitor monotherapy vs. ibrutinib in the treatment of relapsed/refractory CLL/SLL.
Fast-forward to:
Long-term efficacy of ibrutinib as a first-line treatment for patients with CLL/SLL
61af9b9d3ebc500dae6c9a29
Phase III study ELEVATE-RR: Acalabrutinib vs. ibrutinib in high-risk R/R CLL
61728e0a9c305b05957fffcc
Phase III ALPINE study: Ibrutinib vs. zanubrutinib in R/R CLL
6172aa587229d4059475b8a1
Third-generation BTK inhibitors
61af9c642fc9050db56f8dad
BTK inhibitors in CLL/SLL: Summary
61af9d2a2fc9050db56f8dc5
Ibrutinib in CLL/SLL: A clinical case study
61afa3e5f8742a0daf9e3b60
Next-generation BTK inhibitor monotherapy in the treatment of relapsed/refractory B-cell lymphomas
Fast-forward to:
BTK inhibitors in Waldenström's macroglobulinemia
61af989b1b44ef0dbc7092b4
BTK inhibitors in marginal zone lymphoma
6172b2b69787be057b8f8693
BTK inhibitors in mantle cell lymphoma
6172c5ff9c305b05957fffd4
Panel discussion and audience Q&A
Fast-forward to:
How do the pharmacokinetic profiles of BTK inhibitors compare and what are the clinical implications of any differences?
61afb3f41b44ef0dbc70956b
What is the best anticoagulant to use with ibrutinib?
61afb4a81b44ef0dbc709575
If all BTKis were available for CLL/SLL patients which drug would you use?
61afb5e7f8742a0daf9e3cf8
Can you comment on the possibility of fixed-duration regimens with BTKis for CLL/SLL?
61afb679f8742a0daf9e3d03
Why are BTK inhibitors not as effective in the treatment of follicular lymphoma as they are in other B-cell lymphomas?
61afb7252fc9050db56f8f9e
If there were no restrictions on their use, would you favour BTK inhibitors over immunochemotherapy in first-line treatment of Waldenström's macroglobulinemia?
61afb8071b44ef0dbc70958e
Should we consider growth factor prophylaxis with BTK inhibitors and why do we see higher rates of neutropenia without increased infections with next-generation BTK inhibitors?
61afb8d71b44ef0dbc709593
If a patient experienced neutropenia when receiving combination therapy with ibrutinib and venetoclax, which drug would you pause?
61afb96b2fc9050db56f8fb3